Send to

Choose Destination
Saudi Med J. 2000 Nov;21(11):1065-7.

The value of treating the male partner in vaginal candidiasis.

Author information

Department of Obstetrics and Gynecology, King Hussein Medical Center, PO Box 941649, Al Shemesani, Amman, Jordan.



To determine whether treatment of the sexual partners of women with vulvo-vaginal candidiasis with oral Ketoconazole can affect the cure and recurrence rate of candida vaginitis.


A total number of 144 women with vaginal candidiasis were treated with Ketoconazole 400 mg daily for 7 days, and half the male partners were treated with Ketoconazole 400 mg daily for 7 days. All women had physical follow-up examination, and mycological cultures were obtained at one week and four weeks after the start of treatment. The incidence of predisposing factors or of a recurrence history did not differ between treatment groups. Chi-square test was used to determine the significance of difference between the two groups with or without simultaneous treatment of the male partners.


In the control group (untreated partners) 53 of 72 patients were cured after one week, with a cure rate of 74%, compared to 57 of 72 patients (treated partners) with a cure rate of 79%. The recurrence rate in the control group (untreated partners) 4 weeks after the start of treatment was 28 of 53 (53%), compared to 35 of 57 (61%) in the (untreated partners) group. No significant statistical difference was found in the cure and recurrence rates for both groups.


Simultaneous treatment of the male partners with Ketoconazole did not influence either cure rate or recurrence rate in women with vaginal candidiasis.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center